Journal
JOURNAL OF IMMUNOLOGY
Volume 170, Issue 12, Pages 5842-5850Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.170.12.5842
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI31044-11] Funding Source: Medline
Ask authors/readers for more resources
The APC:T cell interface can be effectively targeted with immunotherapeutic proteins. We previously described a unique trans signal converter protein, CTLA-4 . Fas ligand (FasL), that has the inherent capacities to tether the T cell inhibitor FasL (CD95 ligand) to the surfaces of B7 (CD80 and CD86)-positive APC (via CTLA-4:B7 interaction), and in so doing, to simultaneously interfere with B7-to-CD28 T cell activation signals. Given the continuing need for agents capable of inducing allograft tolerance without generalized immunosuppression, we have explored in depth the functional activity of CTLA-4 . FasL in human allogeneic MLR. CTLA-4 . FasL inhibits 1degrees MLR and induces specific hyporesponsiveness in 2degrees MLR, with both effects only partially reversible with exogenous IL-2. Moreover, the presence of exogenous IL-2 during the 1degrees MLR does not affect the induction of hyporesponsiveness upon restimulation. Furthermore, CTLA-4 . FasL enables partial activation of allostimulated T cells, reduces the fraction of actively dividing cells, and increases the percentage of dead cells among dividing T cells. Taken together, these findings suggest that CTLA-4 . FasL-mediated inhibition of secondary alloantigenic responses involves both anergy induction and clonal deletion. Thus, CTLA-4 . FasL, a paradigmatic trans signal converter protein, manifests unique functional properties and emerges as a potentially useful immunotherapeutic for modulating alloresponsiveness.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available